A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Completed · Phase 1/Phase 2

Conditions studied: Age-Related Macular Degeneration

In brief

The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.

Key facts

Study ID

NCT02022501

Run by

Santen Inc.

People needed

10

Starts

2014-01-01

Expected to finish

2016-04-21

Last updated by the study team

2018-04-18

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Bakersfield, California, United States
• Study site — Beverly Hills, California, United States
• Study site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.